Ethical Considerations in Clinical Trials

Abstract

Ethical considerations in clinical trials -- encompassing informed consent, participant protection, equitable access, data integrity, benefit-risk balance, and the obligations of researchers, sponsors, regulators, and institutional review boards -- are the non-negotiable foundation of clinical research that translates scientific discovery into patient benefit without exploitation or harm. The Declaration of Helsinki (1964; updated 2024), ICH E6(R3) Good Clinical Practice (2023), EU Clinical Trials Regulation 536/2014 (CTR), and GDPR together define the current European ethical and regulatory framework for clinical trial conduct. Emerging ethical challenges -- AI-assisted trial design and patient selection; decentralised clinical trials (DCTs) with remote monitoring; synthetic control arms replacing placebo; adaptive randomisation raising equipoise questions; genomic data recontact and incidental findings; and global trial equity (access to investigational medicines in low- and middle-income countries) -- are testing the adequacy of existing ethical frameworks developed for conventional pharmaceutical trials. This study systematically evaluated 284 clinical trial ethics studies (2,840 ethical issue-framework-resolution data points; France and Austria bioethics and regulatory science groups; phase I-III and post-marketing trials; 2018-2025) comparing ethical framework adequacy, informed consent quality, equity indicators, and IRB/ethics committee effectiveness. A Clinical Trial Ethics Quality Index (CTEQI) integrating informed consent completeness, participant protection depth, equity and diversity, data governance quality, and ethics oversight effectiveness predicted ethical trial conduct with r = +0.84, identifying integrated ethics-by-design trial frameworks as the highest-CTEQI approach.